Pharmacological chelation of copper ions by TTM efficiently reduced tumor growth in BRAFV600E-driven melanoma cells, while also demonstrating antimelanoma activity in BRAFV600E inhibitor-resistant [52] and MEK inhibitor-resistant [155] cells. Here, MAP2K7 is linked to melanoma.